Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US5997865

Title:Agonist antibodies against the flk2/flt3 receptor and uses thereof
Inventors:Bennett, Brian D.; South San Francisco, CA 94080
Summary:This is a method for enhancing proliferation or differentiation of hematopoietic cells by contacting the hematopoietic cells with an effective amount of an agonist antibody which binds to the extracellular domain of flk2/flt3 and which activates the tyrosine kinase domain of flk2/flt3. Agonist antibodies are described which bind to the extracellular domain of the flk2/flt3 receptor and thereby activate the intracellular kinase domain. The labeled antibodies are useful as diagnostics for detecting the presence of the flk2/flt3 receptor in primitive hematopoietic cells, and they are able to cause primitive hematopoietic cells to proliferate and/or differentiate and thereby enhance repopulation of mature blood cell lineages in a mammal which has undergone chemo- or radiation therapy or bone marrow transplantation. The antibodies are also useful for treating mammals which have suffered a decrease in blood cells as a consequence of disease or a hemorrhage, among other disorders.
Abstract:Agonist antibodies are disclosed which bind to the extracellular domain of the flk2/flt3 receptor and thereby activate the intracellular kinase domain thereof. The labeled antibodies are useful as diagnostics for detecting the presence of the flk2/flt3 receptor in primitive hematopoietic cells for example. The antibodies are able to cause primitive hematopoietic cells to proliferate and/or differentiate and thereby enhance repopulation of mature blood cell lineages in a mammal which has undergone chemo- or radiation therapy or bone marrow transplantation. The antibodies are further useful for treating mammals which have suffered a decrease in blood cells as a consequence of disease or a hemorrhage, for example.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5997865
Application Number:US1995000434878
Date Filed:04/05/1995
Date Published:07/12/1999
Assignee:None


 
Copyright © 2007 The Institute for Cellular Medicine  6/13/2021